tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Gjertson DW et al. | The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. | 1995 | Transplantation | pmid:8545861 |
| Shin BH et al. | Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents. | 2014 | Transplantation | pmid:24342979 |
| First MR and Fitzsimmons WE | New drugs to improve transplant outcomes. | 2004 | Transplantation | pmid:15201693 |
| Migita K et al. | FK506 markedly enhances apoptosis of antigen-stimulated peripheral T cells by down-regulation of Bcl-xL. | 1999 | Transplantation | pmid:10532544 |
| Yoon SH et al. | CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). | 2013 | Transplantation | pmid:23364483 |
| Hashimoto T et al. | Treatment with FK506 prevents rejection of rat colon allografts. | 1994 | Transplantation | pmid:7516586 |
| Waldman WJ et al. | Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide. | 2001 | Transplantation | pmid:11707749 |
| Ravindran VK et al. | Insulin hyposecretion in nondiabetic, tacrolimus-treated renal transplant recipients more than 6 months posttransplantation. | 2009 | Transplantation | pmid:19543067 |
| Morrissey PE et al. | Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. | 1997 | Transplantation | pmid:9089224 |
| Ericzon BG et al. | The effect of FK506 treatment on pancreaticoduodenal allotransplantation in the primate. | 1992 | Transplantation | pmid:1376501 |
| Sheiner PA et al. | Increased risk of early rejection correlates with recovery of CD3 cell count after liver transplant in patients receiving OKT3 induction. | 1997 | Transplantation | pmid:9355846 |
| Karlsson H and Nässberger L | FK506 suppresses the mitogen-induced increase in lymphocyte adhesiveness to endothelial cells, but does not affect endothelial cell activation in response to inflammatory stimuli. | 1997 | Transplantation | pmid:9355847 |
| Butani L et al. | Amelioration of tacrolimus-induced nephrotoxicity in rats using juniper oil. | 2003 | Transplantation | pmid:12883183 |
| David-Neto E et al. | Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation. | 2017 | Transplantation | pmid:27482958 |
| Ciancio G et al. | A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. | 2006 | Transplantation | pmid:16570006 |
| Reddy KS et al. | Simultaneous kidney-pancreas transplantation without antilymphocyte induction. | 2000 | Transplantation | pmid:10653379 |
| Sood P et al. | Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. | 2012 | Transplantation | pmid:23018881 |
| Jevnikar A et al. | Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. | 2008 | Transplantation | pmid:18852662 |
| Shaffer D et al. | Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506). | 1995 | Transplantation | pmid:7535958 |
| Bronster DJ et al. | Demyelinating sensorimotor polyneuropathy after administration of FK506. | 1995 | Transplantation | pmid:7535959 |
| Ninova D et al. | Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. | 2004 | Transplantation | pmid:15316360 |
| Naesens M and Sarwal MM | Monitoring calcineurin inhibitor therapy: localizing the moving target. | 2010 | Transplantation | pmid:20458272 |
| Watson MJ et al. | Renal function impacts outcomes after intestinal transplantation. | 2008 | Transplantation | pmid:18622288 |
| McLaren A | Tacrolimus pharmacogenetics: bringing the laboratory into the clinic. | 2003 | Transplantation | pmid:14705621 |
| Amundsen R et al. | Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients. | 2009 | Transplantation | pmid:19384170 |
| Jun KR et al. | Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. | 2009 | Transplantation | pmid:19384171 |
| Curran CF et al. | Acute overdoses of tacrolimus. | 1996 | Transplantation | pmid:8932293 |
| Roberts CA et al. | Asymmetric cardiac hypertrophy at autopsy in patients who received FK506 (tacrolimus) or cyclosporine A after liver transplant. | 2002 | Transplantation | pmid:12364862 |
| Ji E et al. | Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. | 2012 | Transplantation | pmid:22992768 |
| Egli A et al. | Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling. | 2013 | Transplantation | pmid:23274966 |
| Hu H et al. | Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling. | 2003 | Transplantation | pmid:12698107 |
| Hebert MF et al. | Interpreting tacrolimus concentrations during pregnancy and postpartum. | 2013 | Transplantation | pmid:23274970 |
| Fujishiro J et al. | Immunologic benefits of longer graft in rat allogenic small bowel transplantation. | 2005 | Transplantation | pmid:15665767 |
| Thai NL et al. | Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. | 2006 | Transplantation | pmid:17198247 |
| Thai NL et al. | Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. | 2006 | Transplantation | pmid:17198253 |
| Ko S et al. | The pharmacokinetic benefits of newly developed liposome-incorporated FK506. | 1994 | Transplantation | pmid:7526494 |
| Holländer GA et al. | Disruption of T cell development and repertoire selection by calcineurin inhibition in vivo. | 1994 | Transplantation | pmid:7526495 |
| Inomata Y et al. | The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. | 1996 | Transplantation | pmid:8600632 |
| Gruessner RW et al. | A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. | 1996 | Transplantation | pmid:8600635 |
| Rezeig MA et al. | Kaposi's sarcoma in liver transplant recipients on FK506: two case reports. | 1997 | Transplantation | pmid:9175820 |
| Vadivel N et al. | Tacrolimus dose in black renal transplant recipients. | 2007 | Transplantation | pmid:17460575 |
| Neuhaus PJ | Optimised first-line FK506-based protocols in liver transplantation: experience from the University Hospital Rudolf Virchow, Berlin. | 1994 | Transplant. Proc. | pmid:7527961 |
| Jordan ML et al. | FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. | 1993 | Transplant. Proc. | pmid:7679827 |
| Fougeray S et al. | Increased body mass index after kidney transplantation in activating transcription factor 6 single polymorphism gene carriers. | 2011 | Transplant. Proc. | pmid:22099811 |
| Jusko WJ and D'Ambrosio R | Monitoring FK 506 concentrations in plasma and whole blood. | 1991 | Transplant. Proc. | pmid:1721260 |
| Tang J et al. | Cytokine Profile in Calcineurin Inhibitor-Induced Chronic Nephrotoxicity in Chinese Liver Transplant Recipients. | 2016 | Transplant. Proc. | pmid:27788813 |
| Millis JM et al. | Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients. | 1996 | Transplant. Proc. | pmid:8623213 |
| Neylan JF | Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. | 1998 | Transplant. Proc. | pmid:9636551 |
| Tanabe K et al. | ABO-incompatible living donor kidney transplantation under tacrolimus immunosuppression. | 2000 | Transplant. Proc. | pmid:11119903 |
| Elmer DS et al. | Metabolic effects of FK 506 (tacrolimus) versus cyclosporine in portally drained pancreas allografts. | 1998 | Transplant. Proc. | pmid:9532159 |
| Zeevi A et al. | Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression. | 1990 | Transplant. Proc. | pmid:1689902 |
| Akselband Y et al. | Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. | 1991 | Transplant. Proc. | pmid:1721292 |
| Klintmalm GB | Clinical use of FK 506 in liver transplantation. | 1996 | Transplant. Proc. | pmid:8623484 |
| Maggard M et al. | Incidence of acute rejection in African-American liver transplant recipients. | 1998 | Transplant. Proc. | pmid:9636607 |
| Yamaguchi M et al. | FK 506 significantly improves transferred insulin gene expression in total pancreatectomized dogs. | 2000 | Transplant. Proc. | pmid:11120255 |
| Morales JM et al. | Tacrolimus, mycophenolate mofetil and corticosteroids as primary immunosuppression after renal transplantation at the Hospital 12 de Octubre, Madrid. | 1999 | Transplant. Proc. | pmid:10576051 |
| Mano A et al. | Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report. | 2009 | Transplant. Proc. | pmid:19917396 |
| Lampreabe I et al. | Toward personalized medicine in renal transplantation. | 2010 | Transplant. Proc. | pmid:20970553 |
| Sato K et al. | Management of living donor liver transplant patients using twice-daily 4-hour intravenous cyclosporine therapy. | 2009 Jan-Feb | Transplant. Proc. | pmid:19249521 |
| Spada M et al. | Monitoring of intestinal myoelectrical activity after isolated small bowel transplantation in FK 506 immunosuppressed pigs. | 1994 | Transplant. Proc. | pmid:7518141 |
| Martinez OM et al. | Molecular markers of Epstein-Barr virus infection in the circulation of transplant recipients. | 1995 | Transplant. Proc. | pmid:7533372 |
| Wojewodzka J et al. | Inhibition of formation of synapses between dendritic cells and lymphocytes in skin lymph in an allogeneic reaction by cyclosporine and tacrolimus. | 2003 | Transplant. Proc. | pmid:14529947 |
| Suga A et al. | Diabetes mellitus after renal transplantation under tacrolimus-based immunosuppression. | 2003 | Transplant. Proc. | pmid:12591391 |
| Koefoed-Nielsen PB et al. | Comparison of the temporal profile of calcineurin inhibition by cyclosporine and tacrolimus in renal transplant patients. | 2005 | Transplant. Proc. | pmid:15919449 |
| Aguirrezabalaga J et al. | Lipid profiles after liver transplantation in patients receiving tacrolimus or cyclosporin. | 2002 | Transplant. Proc. | pmid:12176480 |
| Shapiro R et al. | A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. | 1995 | Transplant. Proc. | pmid:7533432 |
| Gerauer K et al. | Long-term cardiac allograft survival in mice treated with malononitrilamide 715. | 1998 | Transplant. Proc. | pmid:9865349 |
| Whiteside TL et al. | Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506. | 1991 | Transplant. Proc. | pmid:1721356 |
| Hossain MA et al. | Immunosuppression in auxiliary partial liver transplantation with FK506 in rats. | 1997 | Transplant. Proc. | pmid:9414861 |
| Parada MT et al. | Everolimus in lung transplantation in Chile. | 2010 Jan-Feb | Transplant. Proc. | pmid:20172343 |
| Weimer R et al. | Effects of three immunosuppressive regimens on CD4 helper function, B cell monocyte and cytokine responses in renal transplant recipients: 4-month follow-up of a prospective randomized study. | 2002 | Transplant. Proc. | pmid:12270445 |
| Oltean M et al. | FK506 donor pretreatment improves intestinal graft microcirculation and morphology by concurrent inhibition of early NF-kappaB activation and augmented HSP72 synthesis. | 2005 | Transplant. Proc. | pmid:15919508 |
| Jordan ML et al. | Five-year experience with tacrolimus rescue for renal allograft rejection. | 1997 Feb-Mar | Transplant. Proc. | pmid:9123009 |
| Fahlke J et al. | Staggered immunosuppression with the interleukin-2 receptor antagonist daclizumab combined with tacrolimus, prednisolone, and mycophenolate mofetil after orthotopic liver transplantation: a pilot efficacy and safety study. | 2002 | Transplant. Proc. | pmid:12072328 |
| Yamada T et al. | Synergistic effect of FK 506 and trifluoperazine on the immunosuppression in rat small bowel transplantation. | 1996 | Transplant. Proc. | pmid:8907927 |
| Uchida K et al. | Excellent 3-year results following living-donor kidney transplantation and tacrolimus immunosuppression in Japan. | 2002 | Transplant. Proc. | pmid:12176503 |
| Kim YI et al. | FK 506 prevents critical warm ischemia damage to the pig liver and improves hepatic microcirculation. | 1994 | Transplant. Proc. | pmid:7520636 |
| Humar A et al. | Surgical complications requiring early relaparotomy after pancreas transplantation: comparison of the cyclosporine and FK 506 eras. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083256 |
| Sanghvi A et al. | Increased cyclosporine uptake by cells pretreated with FK506 and evidence for binding of both drugs to a common intracellular protein. | 1989 | Transplant. Proc. | pmid:2468204 |
| Winkler M et al. | Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. | 1991 | Transplant. Proc. | pmid:1721389 |
| Grochowicz PM et al. | Synergistic interaction between castanospermine and tacrolimus in a rat heart allograft model. | 1997 Feb-Mar | Transplant. Proc. | pmid:9123296 |
| Gerbase MW et al. | Low doses of mycophenolate mofetil with low doses of tacrolimus prevent acute rejection and long-term function loss after lung transplantation. | 2001 | Transplant. Proc. | pmid:11377481 |
| Yussim A et al. | Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation. | 1996 | Transplant. Proc. | pmid:8962233 |
| Sifontis NM et al. | Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. | 2002 | Transplant. Proc. | pmid:12176554 |
| Lee PC et al. | Cyclosporine or tacrolimus: which is the better partner for myfortic or cellcept? | 2012 | Transplant. Proc. | pmid:22310598 |
| Berloco P et al. | Tacrolimus as cornerstone immunosuppressant in kidney transplantation. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267161 |
| Cooper MH et al. | The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. | 1991 | Transplant. Proc. | pmid:1721419 |
| Yagura K et al. | Pharmacokinetic characteristics of two types of liposomal FK 506. | 1996 | Transplant. Proc. | pmid:8658708 |
| Shi Y et al. | Comparison of Mizoribine and Mycophenolate Mofetil With a Tacrolimus-Based Immunosuppressive Regimen in Living-Donor Kidney Transplantation Recipients: A Retrospective Study in China. | Transplant. Proc. | pmid:28104150 | |
| Lauro A et al. | Liver transplantation for familial amyloid polyneuropathy non-VAL30MET variants: are cardiac complications influenced by prophylactic pacing and immunosuppressive weaning? | 2005 | Transplant. Proc. | pmid:15964382 |
| Flechner SM | Minimizing calcineurin inhibitor drugs in renal transplantation. | 2003 | Transplant. Proc. | pmid:12742481 |
| El-Sabrout R et al. | Improved lipid profile and blood sugar control in pediatric renal transplant recipients using sirolimus-tacrolimus combination. | 2002 | Transplant. Proc. | pmid:12176638 |
| Doesch AO et al. | Increased adherence after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation: a pre-experimental study. | 2010 | Transplant. Proc. | pmid:21168673 |
| Mohamed MA et al. | TGF-beta expression in protocol transplant liver biopsies: a comparative study between cyclosporine-A (CyA) and tacrolimus (FK 506) immunosuppression. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267336 |
| Alvarez-ElÃas AC et al. | CYP3A5 Genotype and Time to Reach Tacrolimus Therapeutic Levels in Renal Transplant Children. | 2016 | Transplant. Proc. | pmid:27110018 |
| Abu-Elmagd K et al. | Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. | 1991 | Transplant. Proc. | pmid:1721451 |
| Cofan F et al. | Oxidation of low-density lipoproteins in renal transplant recipients. | 1999 | Transplant. Proc. | pmid:10500604 |
| Immunosuppression: FK506. | 1988 | Transplant. Proc. | pmid:2450415 | |
| Wu J et al. | Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation. | 1991 | Transplant. Proc. | pmid:1703683 |
| Tanabe K et al. | Long-term results of living kidney transplantation under tacrolimus immunosuppression: a single-center experience. | 1998 | Transplant. Proc. | pmid:9636497 |